Clinical Trial Update: Evaluating the Efficacy and Safety of of HSK44459 in People With Idiopathic Pulmonary Fibrosis [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the efficacy and safety of HSK44459 for idiopathic pulmonary fibrosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• HSK44459

Snippet

Sponsor: Haisco Pharmaceutical Group Co., Ltd. | Conditions: Idiopathic Pulmonary Fibrosis | Phase 2 | Status: COMPLETED